NCT01670162Unknown4 期
On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Proportion of patients with flattening of PED
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
详细描述
A Phase 4 study to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs (the ROLL study).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous enrollment in the study evaluating 2.0mg ranibizumab (NCT 01189019) without early study discontinuation. The last treatment* in the study eye should have been received at least 30 days before enrollment in this study.
- •**last study treatment of either 1.0mg or 2.0mg ranibizumab
- •Presence of persistent fibrovascular pigment epithelial detachment Willing and able to comply iwth clinic visits and study related procedures Provide signed informed consent
排除标准
- •Prior treatment with verteporfin, or external beam radiation therapy, or transpupillary thermotherapy in the study eye.
- •Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye.
- •History of vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye.
- •Concurrent eye disease in the study eye that could compromise visual acuity (e.g. diabetic retinopathy, advanced glaucoma).
- •Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or glaucoma) that, in the opinion of the investigator, could either require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 12 month study period.
- •Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or auto-immune associated uveitis in either eye.
- •Current vitreous hemorrhage in the study eye.
- •History of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye.
- •Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
- •Aphakia, anterior chamber intraocular lens (ACIOL) or unstable posterior chamber intraocular lens (PCIOL).
- •Uncontrolled glaucoma in the study eye (defined as intraocular pressure equal to or greater than 30 despite treatment with anti-glaucoma medication).
- •Pregnant or breastfeeding women.
- •Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraception measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam or jelly).
- •Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
研究组 & 干预措施
3 loading doses, then every 2 months
Experimental
All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
干预措施: Aflibercept (Drug)
结局指标
主要结局
Proportion of patients with flattening of PED
时间窗: 12 months
次要结局
- Mean number of injections(during year 2)
- Mean change in OCT central retinal thickness(18 month and 24 month timepoints)
- Proportion of patients gaining 5 letters or more(18 month and 24 month timepoints)
- Mean Change in Best Corrected Visual Acuity (BCVA)(6 month timepoint and 12 month timepoints)
- Proportion of patients with flattening of PED(18 month and 24 month timepoints)
- Mean number of injections needed(12 month period)
- Mean change in Optical Coherence Tomography (OCT) central retinal thickness(6 month and 12 month timepoints)
- Proportion of patients gaining 5 letters or more letters on Early Treatment Diabetic Retinopathy Study (ETDRS) Chart(6 month and 12 month timepoint)
- Mean change in BCVA(18 month and 24 month timepoint)
研究者
研究点 (3)
Loading locations...
相似试验
撤回
4 期
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal RanibizumabDiabetic Macular EdemaNCT03059277Southeast Clinical Research Associates, LLC
Unknown
4 期
Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)Neovascular Polypoidal Choroidal VasculopathyNCT02092532Southeast Retina Center, Georgia20
已完成
2 期
Role of Intravitreal Aflibercept Injection for the Treatment of Radiation MaculopathyAdverse Effect of Radiation TherapyNCT02586727Larkin Community Hospital40
已完成
2 期
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous ChorioretinopathyCentral Serous ChorioretinopathyNCT01710332Wills Eye12
Unknown
1 期
Treatment for Presumed Ocular HistoplasmosisOcular HistoplasmosisNCT01790893John Kitchens, MD40